An experimental medicine benefited patients with a deadly heart condition in a closely watched Phase 3 trial, lifting the fortunes of its developer, BridgeBio Pharma, and clearing the way for the biotechnology company to seek U.S. approval.
Trial results showed that more study participants with the condition, transthyretin amyloidosis cardiomyopathy, and treated with BridgeBio’s drug instead of a placebo were alive and out of the hospital after two-and-a-half years.
Treatment with the medicine, called acoramidis, also improved patients’ quality of life and heart health, according to data released by BridgeBio Monday. No new safety signals of “potential clinical concern” were observed, the company said.
